Latest News

Latest News

Section 232 Pharma Tariffs: What Changes on 29 September

Section 232 Pharma Tariffs: What Changes on 29 September

On 29 September 2026, Section 232 pharma tariffs reach every company not named in Annex III. The default rate is 100 per cent ad valorem. It applies to patented finished medicines and their associated ingredients. That means active pharmaceutical ingredients and key...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Innovate UK Awards Over £300k SMART Grant

Innovate UK Awards Over £300k SMART Grant

Funding supports the co-design and roll-out of MEMORI, a Class IIb CE-certified SaMD platform, tailored to local clinical teams and systems MEMORI analyses multimodal clinical data in real-time to accurately predict the risk of hospital-acquired infections, alerting...

read more
Biomanufacturing is the Next Industrial Revolution

Biomanufacturing is the Next Industrial Revolution

Across the life sciences sector, a profound shift is underway. Biomanufacturing is poised to become a foundational pillar of how we will make things in the 21st century. Advances in bioreactor design, synthetic biology, and sustainable bioprocessing are enabling...

read more
Statins Safer Than Previously Thought, Major Review Finds

Statins Safer Than Previously Thought, Major Review Finds

Cholesterol-lowering drugs known as statins, taken by millions worldwide, are significantly safer than often perceived, according to a major new scientific analysis. Conducted by the Cholesterol Treatment Trialists’ (CTT) Collaboration and published in The Lancet, the...

read more
Emotion-Aware Companion Robotics: Rethinking Aged Care

Emotion-Aware Companion Robotics: Rethinking Aged Care

Ageing at home is widely accepted as the ideal outcome for older adults, families and healthcare systems, but the way we attempt to support it is deeply flawed. Most technologies deployed into homes today are built on a reactive model of care - where they wait for...

read more
Raising Expectations for Medical Liaisons

Raising Expectations for Medical Liaisons

In the last decade, the Medical Science Liaison role has evolved from a scientific messenger to a field based strategist operating in one of the most highly scrutinized environments in healthcare. That evolution is why board certification is moving from optional...

read more
Innovate UK Awards Over £300k SMART Grant

Innovate UK Awards Over £300k SMART Grant

Funding supports the co-design and roll-out of MEMORI, a Class IIb CE-certified SaMD platform, tailored to local clinical teams and systems MEMORI analyses multimodal clinical data in real-time to accurately predict the risk of hospital-acquired infections, alerting...

read more
Biomanufacturing is the Next Industrial Revolution

Biomanufacturing is the Next Industrial Revolution

Across the life sciences sector, a profound shift is underway. Biomanufacturing is poised to become a foundational pillar of how we will make things in the 21st century. Advances in bioreactor design, synthetic biology, and sustainable bioprocessing are enabling...

read more
Statins Safer Than Previously Thought, Major Review Finds

Statins Safer Than Previously Thought, Major Review Finds

Cholesterol-lowering drugs known as statins, taken by millions worldwide, are significantly safer than often perceived, according to a major new scientific analysis. Conducted by the Cholesterol Treatment Trialists’ (CTT) Collaboration and published in The Lancet, the...

read more
Emotion-Aware Companion Robotics: Rethinking Aged Care

Emotion-Aware Companion Robotics: Rethinking Aged Care

Ageing at home is widely accepted as the ideal outcome for older adults, families and healthcare systems, but the way we attempt to support it is deeply flawed. Most technologies deployed into homes today are built on a reactive model of care - where they wait for...

read more
Raising Expectations for Medical Liaisons

Raising Expectations for Medical Liaisons

In the last decade, the Medical Science Liaison role has evolved from a scientific messenger to a field based strategist operating in one of the most highly scrutinized environments in healthcare. That evolution is why board certification is moving from optional...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Further News

Biotech IPO 2026: From Drought to Record-Breaking Deals

The first half of 2026 has delivered a decisive answer to a question the life sciences industry has been asking for years: is the biotech IPO window finally open again? The drought bottomed out in 2025, when fewer biotechs went public than in any year in at least half...

Want the FDA to Make Peptides More Accessible?

As the FDA considers reclassifying seven popular peptides, experts say the decision could change how patients access these compounds. As the FDA evaluates whether several commonly used peptides should become eligible for pharmacy compounding, the outcome could...

The Scientist in the Loop: Why Biopharma R&D Still Needs Human Judgment

Two years into the biopharma industry's most sustained experiment with artificial intelligence, the honest answer to "what has changed" is not the one most conference keynotes suggest. It is not that biopharma AI now runs the laboratory. It is that AI has become very...

How Can We Protect a Failing Heart Using Your Own Mini-Hearts?

Cardiovascular disease in Australia claims one life every 12 minutes. The irreversible damage to the heart is known as heart failure, a condition that progressively prevents the heart from providing the proper amount of blood to our body. This means that patients will...

Early Recognition of Actinic Keratosis in an Aging Population

Healthy aging has changed dramatically over the past several decades. Preventive medicine has expanded well beyond treating disease to identifying health risks before they become serious problems. Today, patients routinely discuss blood pressure, cholesterol,...

Psychedelic Medicine Commercialization: Altered Perceptions

Lilly’s acquisition of AtaiBeckley validates the therapeutic and economic promise of rapid-acting neuroplastogens. It also raises a harder question: can commercial teams redesign the beliefs surrounding these medicines as effectively as scientists are redesigning the...

Safety, Toxicology, and Risk Assessment of Essential Oils

Essential oils are complex mixtures of volatile phytochemicals that have long been incorporated into traditional medicine, personal care products, aromatherapy, and topical therapeutic formulations. Their diverse biological activities—including antimicrobial,...

Weekly News Roundup | 27 July 2026

Life science news 27 July 2026: GSK wins its first lung cancer approval with a selective ROS1 inhibitor, Lilly's triple agonist retatrutide delivers up to 22.6 per cent weight loss in two pivotal trials, and the MHRA clears what it calls the world's first lower-carbon...

The Preclinical Bottleneck: Why Traditional Antibody Discovery Hits a Wall

The therapeutic landscape has been undeniably transformed by monoclonal antibodies (mAbs). From oncology to autoimmune disorders and emerging infectious diseases, mAbs represent one of the most powerful modalities in modern medicine. However, the initial phase of...

Exploring the Role of Astrocytes in MND With Translatable Human Cell Models

Motor Neuron Disease (MND) is characterised by the progressive loss of motor neurons. Despite years of research into the disease, effective treatments remain extremely limited and half of patients pass away within two years of diagnosis. To date there is no cure for...

Clinical Trials Roundup | 24 July 2026

Merck's enlicitide receives FDA approval as the first oral PCSK9 inhibitor for adults with hypercholesterolaemia, GSK's zidesamtinib earns FDA approval as a next-generation ROS1 selective inhibitor for previously treated non-small cell lung cancer, GSK's camlipixant...

New Platform Pairly’s Rapid Growth Highlights Urgent Need to Simplify UK Social Care

An entrepreneur whose father died before care at home could be arranged has built a digital platform that is transforming how families find care across the UK. After experiencing first-hand how difficult it was to arrange support for his own father, Pairly co-founder...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.